BPC-157 vs Melanotan I
Extensively Studied vs FDA Approved
synergistic Mechanism-based · 45% Both BPC-157 and Melanotan I promote collagen synthesis. Complementary mechanisms may enhance connective tissue repair and skin quality.
Molecular Data
BPC-157 Melanotan I
Weight 1,419.53 Da 1646.88 Da
Half-life <30 minutes ~30 minutes
Chain 15 amino acids —
Type Pentadecapeptide Synthetic peptide analog
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Melanotan I
01 Precise dosing control with rapid tanning onset
02 Flexible home administration unlike implant version
03 Visible tanning within 1-2 weeks with UV exposure
04 Enhanced photoprotection through increased melanin
05 More selective for MC1R than Melanotan II
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Melanotan I
Loading: 0.25-0.5mg daily; Maintenance: 0.25-0.5mg 2-3x weekly / Loading phase: 1-2x daily for 1-2 weeks, then maintenance 2-3x weekly
Loading phase 0.25-0.5mg 1-2x daily for 1-2 weeks
Maintenance 0.25-0.5mg 2-3x weekly
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Melanotan I
Mild nausea
Facial flushing
Reduced appetite
Increased mole/freckle pigmentation
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Research Evidence
BPC-157 Melanotan I
Status Extensively Studied FDA Approved
References 8 studies 3 studies
Latest July 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.